report revenue street estimate soliri strensiq beat non-
gaap ep also beat lower expens full year guidanc up
remain conserv strong outlook soliri gmg strensiq
drive rapidli forward pnh submiss alreadi complet
 eu multipl trial along japanes submiss
expect begin bd effort on-going rebuild pipelin
believ next near-tim stock move catalyst would nmosd data
solid perform report financi revenu
q/q y/i well consensu
q/q y/ meanwhil non-gaap ep q/q
y/i also significantli ahead consensu q/q
y/i driven lower sg tax expens favor order
time larg pickup sale across portfolio base result
rais financi guidanc see tabl think
conserv readili achiev estim
compani guidanc rang price headwind continu estim
impact metabol attribut soliri
strong soliri sale soliri q/q y/i sale
well ahead consensu vs y/i volum
growth sale also posit impact favor order
time ahead juli weekend along tender order ex-u
market estim guidanc up
grow contribut mg
rang pnh ahu patient receiv soliri continu grow
compani report highest number new patient start net
patient add pnh sinc launch manag note
exclud item headwind tender order etc pnh
ahu q/q volum growth high singl digit level
manag note mg launch outpac soliri launch
pnh ahu patient receiv therapi end
guidanc
guidanc
tr target
june patient enrol onesourc program offer
alexion provid educ assist access soliri
compani effort result commerci coverag live
manag note prescrib physician major
commun neurologist treat one mg patient
soliri moreov manag note
patient nonrespond real world experi
indic rate significantli less potenti make
mg opportun larger expect ex-u mg launch
germani continu progress slowli compani expect
due lack clinic trial experi region estim gmg
indic contribut sale
nmosd trial complet today manag report neuromyel optica spectrum
disord nmosd trial soliri complet final studi visit last patient
larg bolu data analyz manag work dilig studi site lock
databas come month data trial expect
consensu vs y/i volum growth though sale benefit
favor order time metabol guidanc rais
continu growth strensiq manag note see strensiq
provid
sale broadli in-lin street expect vs volum growth
y/i compani continu expand lab test target popul nash nafld famili
hypercholesterolemia etc elev alt level like suffer lal-d
submiss track mid-jun submit applic approv
pnh fda use rare diseas prioriti review voucher ema
applic support data two larg phase trial evalu patient naiv
to- histori soliri usag prioriti review reduc fda evalu period
month typic thu expect approv fda
market regulatori submiss japan plan later year addit mg/ml
high concentr formul also develop design reduc
infus time hr minut
enrol pivot phase trial ahu
complet open label trial adult adolesc ahu patient nave complement
inhibitor therapi util weight base dose follow initi load
dose scheme primari endpoint complet tma respons week top-line data
trial expect regulatori file expect follow approv
pnh
phase trial iv target initi later year could
potenti file late earli
multipl subq program readi get run weekli subq
phase bridg studi slate start studi use pk-base endpoint look
trough concentr serv basi registr pnh ahu
expect trial start target enrol fewer patient believ
potenti file could occur addit subq program formul
co-administ halozym enhanz technolog could extend
page
dose interv either qm qw cta submit eu phase
studi expect begin
recal mid-april announc acquisit wilson therapeut wtx-se rate
bring late-stag asset wilson diseas see note
manag note power phase trial superior
evalu trial enhanc potenti liver biopsi could enhanc potenti
label approv
reflect commerci trend rais total revenu estim
non-gaap ep estim sum-of-the-part base npv-deriv pt
remain unchang
page
page
producteventtimingpotenti updat patent coverag phase prevent trial relaps nmosd phase studi second-gen sub-q phase trial proof-of-concept studi immunoglobulin nephropathi regulatori submiss singl pk-base phase bridg studi weekli sub-q data phase treatment-nav adolesc adult ahu studi decis file adolesc adult file gmglate phase approv addit approv addit strh analysi compani reportscompl franchisemetabol franchisesolirisindicationsnpv per sharesoliri current price-to-earnings price-to-earnings revenu multipl strh analysi compani report last updat part sotp npv valuat alexion pharmaceut inc
page
estim estim changestrhactualconsensusa vs street mm except per share diff mm except per share data priorcurr chang chang mm except per share data priorcurr chang total total total total total total total total total opex opex opex strh analysi consensu provid last updat perform guidanc priornewstrh consensu total revenu franchis margin changetax rate strh analysi consensu provid last updat number averag data point may add precis inc
page
soliri yoy yoy metabol franchis gross oper oper incom non-gaap tax incom loss net incom net gaap yoy ep exclud stock-comp item strh analysi compani report last updat mm inc
biotechnolog compani engag research develop
commerci life-transform therapeut treat patient sever ultra-rar diseas
product offer fall two broad franchis complement metabol core
alexion complement franchis soliri world first termin complement inhibitor approv
treatment patient paroxysm nocturn hemoglobinuria pnh patient atyp
hemolyt urem syndrom ahu two approv product metabol franchis includ
strensiq enzym replac therapi ert approv hypophosphotasia
kanuma also ert approv lysosom acid lipas defici lal-d alexion found
headquart cheshir ct
alexion premier orphan disease-focus biotech two franchis complement
metabol year experi complement biolog flagship product soliri
standard-of-car two ultra-rar blood disord pnh ahu deep complement pipelin
slate extend domin next decad expect share outperform
potenti upward earn revis clinical/regulatori newsflow
valuat risk
pt base sum-of-the-part sotp net-present-valu npv analysi
includ estim npv soliri cash flow pnh ahu mg strensiq cash flow
kanuma cash flow lal-d compani current net cash posit use
discount rate termin growth rate believ appropri compani
similar alexion base assumpt npv suggest fair valu
contribut pipelin candid model leav substanti room potenti upsid
alexion busi larg depend commerci success soliri strensiq kanuma
product could face intens competit newer emerg therapeut products/
class unexpect advers event could hamper accept among physician
patient
alexion launch strensiq kanuma earli stage new sale market
distribut strategi capabl metabol portfolio yet proven market size
ultra-orphan indic lal-d smaller project anticip futur sale
could significantli impact
drug-pric strategi come increas scrutini lawmak far biotech
compani abl take frequent price increas product could moder
go forward ou territori government-sponsor healthcar system pay healthcar
cost product could subject increas price reimburs pressur due price control
impos govern mani countri
alexion growth conting novel product continu label
expans new indic soliri nmo could face clinic regulatori setback
prospect growth driver critic long-term success alexion
alexion busi signific exposur fluctuat foreign currenc exchang rate
approxim two-third revenu gener outsid us past year addit alexion
could face signific challeng south america brazil argentina commod depend
economi given recent turmoil oil commod
compani mention note
yatin suneja herebi certifi view express research report accur reflect
person view subject compani secur also certifi
page
receiv direct indirect compens exchang express specif
recommend report
